Sector: MedicalShire Pharmaceuticals Group plc (NASDAQ: SHPGY)
Ranking History
Scan Date: | 10/27/2009 |
Sector: | Medical |
Funamental : | 153 |
Technical : | 93 |
Performance : | 210 |
Overall: | 168 |
Number of Stocks: | 306 |
Scan Date: | 10/20/2009 |
Sector: | Medical |
Funamental : | 158 |
Technical : | 206 |
Performance : | 238 |
Overall: | 245 |
Number of Stocks: | 305 |
Scan Date: | 10/15/2009 |
Sector: | Medical |
Funamental : | 147 |
Technical : | 229 |
Performance : | 220 |
Overall: | 240 |
Number of Stocks: | 305 |
Headlines
- Porter Novelli Wins Gold from Medical Marketing & Media for Best Unbranded TV Ad
Nov 04, 2009 09:38 AM | OMC, SHPGY
- Shire Extends Agreement with Medidata Solutions for Trial Planning Products
Nov 04, 2009 08:30 AM | SHPGY
- FDA Grants Priority Review for Shire's velaglucerase alfa for Type 1 Gaucher Disease
Nov 04, 2009 07:03 AM | SHPGY
- SHIRE PLC - FDA Grants Priority Review for Shire’s velaglucerase
Nov 04, 2009 07:02 AM | SHPGY
- New Shire Board Member
Nov 02, 2009 05:26 AM | SGP, SHPGY
- Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD
Oct 30, 2009 03:00 PM | SHPGY
- Shire Continues to Deliver Excellent Growth From Core Products
Oct 30, 2009 09:13 AM | SHPGY
- New Data Show Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Demonstrated Significant ADHD Symptom Reduction when Assessed Using the Oppositional Subscale of the Conners' ADHD Rating Scale
Oct 29, 2009 06:30 PM | SHPGY
- Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates
Oct 29, 2009 04:06 PM | FOLD, SHPGY
- Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30
Oct 29, 2009 02:07 PM | SHPGY
- Evening Standard, London, Market Report Column
Aug 19, 2009 03:50 PM | BTI, HBC, JPM, LYG, SANYY, SHPGY
- Daily Mail, London, Market Report Column
Aug 18, 2009 04:54 PM | BCS, IBM, LGGNY, LYG, SHPGY, TEO
- Daily Mail, London, Market Report Column - Apr 24 2009 3:54PM
Apr 24, 2009 03:53 PM | GSK, MAKSY, PFE, SHPGY
- Shire Opens Office in Japan, Appoints New MD
Feb 20, 2009 02:30 PM | SHPGY
- Movers: AIG, Lehman, Healthways, LDK Solar, Noven Pharma
Aug 26, 2008 10:55 AM | AIG, AMD, BRCM, FNM, FRE, GILT
- Impax Laboratories Commences Shipment of Generic Adderall XR® Capsules, 5mg, 10mg, 15mg, 20mg, 25mg, and 30mg
Oct 01, 2009 03:54 PM | IPXL, SHPGY
- Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform
Aug 24, 2009 08:01 AM | SHPGY
- Shire Initiates Two Adult ADHD Outreach Programs
Aug 17, 2009 09:01 AM | SHPGY
- Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA
Aug 03, 2009 02:01 AM | SHPGY
- FDA Issues Complete Response Letter for INTUNIV(TM) (guanfacine) Extended Release for the Treatment of ADHD in Children and Adolescents
Jul 28, 2009 02:01 AM | SHPGY
- Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once-Daily Vyvanse(R) (lisdexamfetamine dimesylate) CII Provided Significant Improvement of ADHD Symptoms for Children at 13 Hours After Administration
Jul 22, 2009 09:03 AM | SHPGY
- Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
Jul 16, 2009 02:01 AM | SHPGY
- Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
Jul 06, 2009 03:02 PM | SHPGY
- Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment
Jul 01, 2009 09:03 AM | SHPGY
- FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD
Jun 01, 2009 09:01 AM | SHPGY
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
SHPGY
|
Compare to S&P
|
| YTD |
19.03 %
|
3.76 %
|
| 4 Weeks |
6.18 %
|
5.05 %
|
| 12 Weeks |
8.05 %
|
5.37 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: -53.12 %
|
|
EPS Growth in Last Year: -36.84 %
|
|
Sales Growth in Last Quarter: -22.96 %
|
|
Sales Growth in Last Quarter: -18.77 %
|
|
